Business Context and Reporting Period
Company: Corcept Therapeutics Incorporated (CORT)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: Corcept is a commercial-stage biopharmaceutical company focused on treating severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating cortisol. Its primary commercial product is Korlym (mifepristone) for hypercortisolism (Cushing's syndrome), for which an authorized generic was launched in June 2024. The company is advancing a pipeline of selective cortisol modulators, including relacorilant (hypercortisolism and ovarian cancer), dazucorilant (ALS), and miricorilant (MASH).
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Product Revenue, Net | $207,638 | $182,546 | $559,282 | $493,150 |
| Cost of Sales | $4,596 | $2,867 | $10,432 | $7,926 |
| Gross Margin % | 97.8% | 98.4% | 98.1% | 98.4% |
| Operating Expenses | $197,419 | $135,948 | $518,972 | $381,461 |
| Income from Operations | $10,219 | $46,598 | $40,310 | $111,689 |
| Net Income | $19,668 | $47,213 | $75,364 | $110,463 |
| Diluted EPS | $0.16 | $0.41 | $0.62 | $0.98 |
| Cash & Cash Equivalents | $125,138 | $127,665 | $125,138 | $137,289 |
| Marketable Securities | $399,102 | $475,500 | $399,102 | $475,500 |
| Total Liquidity | $524,240 | $603,165 | $524,240 | $603,165 |
Note: Liquidity figures represent the sum of Cash, Cash Equivalents, Short-term, and Long-term Marketable Securities.
Material Changes vs. Prior Period
- Revenue Growth: Net product revenue increased 13.7% in Q3 2025 and 13.4% in the nine-month period compared to 2024. This growth was driven by a 42.5% increase in sales volume, partially offset by a 20.2% decrease in average price due to the mix shift toward the lower-priced authorized generic version of Korlym.
- Operating Expenses: Total operating expenses rose significantly, increasing 45.2% in Q3 and 36.0% year-to-date. Selling, general, and administrative (SG&A) expenses surged 68.1% in Q3 (from $73.7M to $124.0M) due to expanded sales and marketing activities. R&D expenses increased 16.0% in Q3, driven by advancement of development programs.
- Profitability Decline: Despite revenue growth, Net Income decreased 58.4% in Q3 and 31.8% year-to-date. Operating income dropped 78.1% in Q3 due to the disproportionate rise in SG&A and R&D costs relative to revenue.
- Share Repurchases: The company aggressively utilized its capital, repurchasing $172.9 million of common stock in the first nine months of 2025, compared to $15.7 million in the same period in 2024. As of September 30, 2025, $11.4 million remained available under the $200 million authorization.
- Tax Impact: The company recorded an income tax benefit of $4.4 million in Q3 2025, compared to an expense of $5.7 million in Q3 2024. This shift was influenced by the enactment of the "One Big Beautiful Bill Act" in July 2025, which allowed for immediate expensing of domestic R&D expenses, reducing current tax liabilities.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Relacorilant (Hypercortisolism): An NDA was submitted in December 2024 with a PDUFA date of December 30, 2025. The application is supported by positive results from the GRACE and GRADIENT trials.
- Relacorilant (Ovarian Cancer): An NDA for relacorilant in combination with nab-paclitaxel for platinum-resistant ovarian cancer was submitted in July 2025, with a PDUFA date of July 11, 2026. The ROSELLA trial met its primary endpoint for progression-free survival.
- Dazucorilant (ALS): The Phase 2 DAZALS trial did not meet its primary endpoint but showed a statistically significant reduction in early death. A pivotal Phase 3 trial is planned for 2026.
- Liquidity: Management expects to fund operations and R&D for the next 12 months and beyond without raising additional capital, citing $524.2 million in cash and marketable securities.
Risks and Contingencies
- Generic Competition: Teva launched a generic version of Korlym in January 2024. Corcept is appealing a District Court ruling that found Teva's product non-infringing. The availability of generics from Teva, Sun, and Hikma poses a risk to revenue and pricing power.
- Regulatory and Political Uncertainty: The filing highlights risks related to the "One Big Beautiful Bill Act" (OBBBA) of 2025, which significantly reduces Medicaid funding and may increase costs for patient assistance programs. Additionally, a government shutdown beginning October 1, 2025, has furloughed FDA employees, potentially delaying NDA reviews.
- Legal Proceedings:
- Teva Antitrust Litigation: Teva filed an antitrust lawsuit in June 2024; a trial is scheduled for January 2027.
- Government Investigation: The U.S. Attorney's Office for the District of New Jersey is investigating the sale and promotion of Korlym. Corcept is not currently a defendant but is cooperating.
- Patent Litigation: Corcept is appealing a Federal Circuit decision regarding patent infringement by Teva's generic Korlym.
Investor Verification Checklist
- Generic Impact: Verify the current market share and pricing pressure exerted by Teva's generic Korlym and the authorized generic launched by Corcept.
- Regulatory Timelines: Monitor the status of the FDA review for relacorilant (PDUFA: Dec 30, 2025) and the potential impact of the October 2025 government shutdown on this timeline.
- SG&A Efficiency: Assess whether the 68% increase in SG&A expenses in Q3 2025 will yield sustainable revenue growth or if it represents a temporary spike in commercialization costs.
- Capital Allocation: Confirm the remaining balance of the stock repurchase program ($11.4M) and the company's strategy for deploying remaining cash reserves.
- Legal Exposure: Track the outcome of the Teva patent appeal and the status of the New Jersey government investigation regarding Korlym promotion.